188 related articles for article (PubMed ID: 15214911)
1. Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara).
Didona B; Benucci R; Amerio P; Canzona F; Rienzo O; Cavalieri R
Br J Dermatol; 2004 Jun; 150(6):1198-201. PubMed ID: 15214911
[TBL] [Abstract][Full Text] [Related]
2. Topical imiquimod as treatment for different kinds of cutaneous lymphoma.
Coors EA; Schuler G; Von Den Driesch P
Eur J Dermatol; 2006; 16(4):391-3. PubMed ID: 16935796
[TBL] [Abstract][Full Text] [Related]
3. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.
Duvic M; Tetzlaff MT; Gangar P; Clos AL; Sui D; Talpur R
J Clin Oncol; 2015 Nov; 33(32):3759-65. PubMed ID: 26261247
[TBL] [Abstract][Full Text] [Related]
4. Long-term remission of primary cutaneous neutrophil-rich CD30+ anaplastic large cell lymphoma treated with topical imiquimod. A case report.
Calista D; Riccioni L; Bagli L; Valenzano F
J Eur Acad Dermatol Venereol; 2016 May; 30(5):899-901. PubMed ID: 25809386
[No Abstract] [Full Text] [Related]
5. Successful treatment of primary cutaneous follicle centre lymphoma with topical 5% imiquimod.
Stavrakoglou A; Brown VL; Coutts I
Br J Dermatol; 2007 Sep; 157(3):620-2. PubMed ID: 17553050
[No Abstract] [Full Text] [Related]
6. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.
Urosevic M; Dummer R; Conrad C; Beyeler M; Laine E; Burg G; Gilliet M
J Natl Cancer Inst; 2005 Aug; 97(15):1143-53. PubMed ID: 16077073
[TBL] [Abstract][Full Text] [Related]
7. Topical imiquimod therapy for cutaneous T-cell lymphoma.
Do JH; McLaughlin SS; Gaspari AA
Skinmed; 2003; 2(5):316-8. PubMed ID: 14673267
[No Abstract] [Full Text] [Related]
8. Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier imiquimod.
Suchin KR; Junkins-Hopkins JM; Rook AH
Arch Dermatol; 2002 Sep; 138(9):1137-9. PubMed ID: 12224972
[No Abstract] [Full Text] [Related]
9. Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy.
French LE; Shapiro M; Junkins-Hopkins JM; Vittorio CC; Rook AH
J Am Acad Dermatol; 2001 Dec; 45(6):914-8. PubMed ID: 11712039
[TBL] [Abstract][Full Text] [Related]
10. Primary cutaneous CD30+ anaplastic large cell lymphoma responds to imiquimod cream.
Ehst BD; Dréno B; Vonderheid EC
Eur J Dermatol; 2008; 18(4):467-8. PubMed ID: 18573730
[No Abstract] [Full Text] [Related]
11. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience.
Tillman DK; Carroll MT
Cutis; 2007 Mar; 79(3):241-8. PubMed ID: 17674590
[TBL] [Abstract][Full Text] [Related]
12. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma.
Bong AB; Bonnekoh B; Franke I; Schön M; Ulrich J; Gollnick H
Dermatology; 2002; 205(2):135-8. PubMed ID: 12218228
[TBL] [Abstract][Full Text] [Related]
13. Topical imiquimod treatment of lentigo maligna: clinical and histologic evaluation.
Kupfer-Bessaguet I; Guillet G; Misery L; Carre JL; Leroy JP; Sassolas B
J Am Acad Dermatol; 2004 Oct; 51(4):635-9. PubMed ID: 15389205
[TBL] [Abstract][Full Text] [Related]
14. Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors.
Xiong Z; Ohlfest JR
J Immunother; 2011 Apr; 34(3):264-9. PubMed ID: 21389872
[TBL] [Abstract][Full Text] [Related]
15. Treatment of extramammary Paget disease with topical imiquimod cream: case report and literature review.
Cohen PR; Schulze KE; Tschen JA; Hetherington GW; Nelson BR
South Med J; 2006 Apr; 99(4):396-402. PubMed ID: 16634252
[TBL] [Abstract][Full Text] [Related]
16. Two cases of squamous cell carcinoma treated with topical imiquimod 5%.
Oster-Schmidt C
J Eur Acad Dermatol Venereol; 2004 Jan; 18(1):93-5. PubMed ID: 14678542
[TBL] [Abstract][Full Text] [Related]
17. Imiquimod 5% cream for the treatment of nasal lesion of metastatic renal cell carcinoma.
Asakura M; Miura H
Dermatol Ther; 2011; 24(3):375-7. PubMed ID: 21689248
[TBL] [Abstract][Full Text] [Related]
18. Innovative uses of imiquimod.
Vender RB; Goldberg O
J Drugs Dermatol; 2005; 4(1):58-63. PubMed ID: 15696986
[TBL] [Abstract][Full Text] [Related]
19. Imiquimod and the treatment of cutaneous T-cell proliferative diseases: at the threshold.
Herbert WC
Skinmed; 2003; 2(5):273-4. PubMed ID: 14673259
[No Abstract] [Full Text] [Related]
20. Imiquimod 5% cream as a therapeutic option for extramammary Paget's disease.
Sawada M; Kato J; Yamashita T; Yoneta A; Hida T; Horimoto K; Sato S; Uhara H
J Dermatol; 2018 Feb; 45(2):216-219. PubMed ID: 29115681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
